Current Pharmaceutical Design - Volume 29, Issue 18, 2023

As the World Health Organization (WHO) declared, vaccines prevent an average of 2-3 million deaths yearly from diseases. However, effective prophylactic and therapeutic vaccines have yet to be developed for eradicating the deadliest diseases, viz., types of cancer, malaria, human immunodeficiency virus (HIV), and most serious microbial infections. Furthermore, scores of the existing vaccines have disadvantages, s Read More

Scintigraphic imaging was satisfactory in animal experiments, i.e., in the radioimmunodetection with 125J anti-tissue polypeptide antigen monoclonal antibodies and implanted HELA cell carcinomas. Unlabeled anti- mouse antibodies (AMAB), in a surplus of 40:1, 200:1 and 4000:1 compared to the radioactive antibody, were administered five days after administering the 125I anti-TPA antibody (RAAB). In immunosci Read More

Local anesthetic (LA) compounds decrease the permeability of the ion channels to sodium, which in turn, reduces the rate of depolarization. These agents (a.k.a. -caines) are also used to depress mucosal sensations, e.g., gag reflex in the form of topical anesthetics. Overdose of LA can lead to local anesthetic systemic toxicity (LAST), which is the precursor of potentially lethal consequences on clinical grounds. There is a wide ar Read More

Curcumin is a potent bioactive compound of Curcuma longa. Curcumin comprises a broad spectrum of biological activities, including hepatoprotective, anticancer, antimicrobial, anti-inflammatory, antitumor, anti- oxidant, etc. However, its low aqueous solubility, rapid excretion, and poor bioavailability restricted its therapeutic uses. To resolve these issues, novel nano-systems have now been developed to increas Read More

Viral disease is a well-known cause of a significant impact on economic losses and threatens developed and developing societies. High mutation rates and the lack of ability of conventional formulations to target specific cells pose substantial hurdles to the successful treatment of viral diseases. We conducted a preliminary search by a standard procedure. With hand searching, we conducted an advanced search across Read More

Background: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are mainly known as anti-hypertensive drugs. Recent evidence suggests their anti-tumor potential against renal cancer. More than one-fourth of patients present with metastasis on their first visit. Objective: The purpose of the current study was to examine the potential clinical impact of ACEI/ARB on metastatic renal cell c Read More